- Home
- FCN vs LEGN Comparison
FCN vs LEGN Comparison
Compare FCN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCN
- LEGN
- Stock Information
- Founded
- FCN 1982
- LEGN 2014
- Country
- FCN United States
- LEGN United States
- Employees
- FCN N/A
- LEGN N/A
- Industry
- FCN Professional Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FCN Consumer Discretionary
- LEGN Health Care
- Exchange
- FCN Nasdaq
- LEGN Nasdaq
- Market Cap
- FCN 5.5B
- LEGN 5.4B
- IPO Year
- FCN 1996
- LEGN 2020
- Fundamental
- Price
- FCN $166.93
- LEGN $34.60
- Analyst Decision
- FCN Hold
- LEGN Strong Buy
- Analyst Count
- FCN 2
- LEGN 11
- Target Price
- FCN $175.50
- LEGN $74.10
- AVG Volume (30 Days)
- FCN 314.9K
- LEGN 1.0M
- Earning Date
- FCN 10-23-2025
- LEGN 08-11-2025
- Dividend Yield
- FCN N/A
- LEGN N/A
- EPS Growth
- FCN N/A
- LEGN N/A
- EPS
- FCN 7.09
- LEGN N/A
- Revenue
- FCN $3,662,887,000.00
- LEGN $796,838,000.00
- Revenue This Year
- FCN $1.42
- LEGN $70.75
- Revenue Next Year
- FCN $6.21
- LEGN $52.47
- P/E Ratio
- FCN $23.73
- LEGN N/A
- Revenue Growth
- FCN N/A
- LEGN 74.75
- 52 Week Low
- FCN $151.75
- LEGN $27.34
- 52 Week High
- FCN $231.65
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- FCN 48.80
- LEGN 31.32
- Support Level
- FCN $167.17
- LEGN $35.10
- Resistance Level
- FCN $172.24
- LEGN $36.80
- Average True Range (ATR)
- FCN 3.04
- LEGN 1.34
- MACD
- FCN -0.14
- LEGN -0.39
- Stochastic Oscillator
- FCN 66.21
- LEGN 0.26
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.